Regulation of peroxisome proliferator-activated receptor-alpha expression during lung inflammation.

@article{Becker2008RegulationOP,
  title={Regulation of peroxisome proliferator-activated receptor-alpha expression during lung inflammation.},
  author={J. Becker and C. Delayre-Orthez and N. Frossard and F. Pons},
  journal={Pulmonary pharmacology \& therapeutics},
  year={2008},
  volume={21 2},
  pages={
          324-30
        }
}
Peroxisome proliferator-activated receptor-alpha (PPARalpha) is implicated in the control of airway inflammation. However, little is known so far about PPARalpha expression and regulation in the lung. Our aim was to assess PPARalpha expression in the lung from normal mice, as well as to investigate its regulation during airway inflammation or in response to anti-inflammatory agents. The PPARalpha activator, fenofibrate, the glucocorticoid, dexamethasone or vehicle was administered to normal… Expand
Tumour necrosis factor alpha down-regulates the expression of peroxisome proliferator activated receptor alpha (PPARα) in human hepatocarcinoma HepG2 cells by activation of NF-κB pathway.
TLDR
The results suggest that TNF-α might, at least in part, suppress PPARα expression through activation of IKK/p50/p105/p65 pathway and phosphorylation of p65 at Ser468 and Ser536 may play a crucial role in the mechanism that limits PPAR α production in the human HepG2 cells. Expand
Peroxisome proliferator-activated receptor-α reduces inflammation and vascular leakage in a murine model of acute lung injury
TLDR
Activation of peroxisome proliferator-activated receptor-α by WY 14,643 reduced acute lung injury and vascular leakage and fibrates may possess beneficial effects in acute pulmonary diseases beyond their lipid-lowering capability. Expand
The peroxisome proliferator‐activated receptor alpha agonist fenofibrate decreases airway reactivity to methacholine and increases endothelial nitric oxide synthase phosphorylation in mouse lung
TLDR
It is demonstrated that fenofibrate downregulates airway reactivity to methacholine in the mouse and suggested that this effect could involve an increase in NO generation through an enhanced eNOS phosphorylation. Expand
Zinc gluconate is an agonist of peroxisome proliferator‐activated receptor‐α in the epidermis
TLDR
It is suggested that zinc gluconate may be a PPAR‐α agonist, which might play a role in the anti‐inflammatory activity of this molecule. Expand
Macrophages, PPARs, and Cancer
TLDR
Current knowledge provides a sound basis for the clinical evaluation of PPAR ligands as chemopreventive agents in chronic inflammation-associated cancer development, while cautioning against the unthoughtful application of these agents as cancer therapeutics. Expand
PPARα as a therapeutic target in inflammation-associated diseases
TLDR
This review is especially focused on the global action of PPARα on inflammation in several tissues from data obtained in numerous cell types and in vivo models exposed to inflammatory stimuli. Expand
Increased nitric oxide production and gender-dependent changes in PPARα expression and signaling in the fetal lung from diabetic rats
TLDR
There are gender-dependent changes in PPAR α expression and signaling in the fetal lung from diabetic rats, although PPARα activation prevents maternal diabetes-induced lung NO overproduction in both male and female fetuses. Expand
Regulation of peroxisome proliferator‐activated receptors (PPAR) α and ‐γ of rat brain astrocytes in the course of activation by toll‐like receptor agonists
TLDR
It is reported that lipopolysaccharide, peptidoglycan, and flagellin, which are agonists of TLR4, TLR1/2, and TLR5, respectively, exert time‐ and nuclear factor kappa‐light‐chain‐enhancer of activated B cells‐dependent suppression of mRNA, protein and activity of PPARα and PPARγ. Expand
Rosiglitazone as a regulator of innate immunity in a cell model of hyperglycemia
TLDR
Rosiglitazone, an agonist of PPARγ, decreased expression level ofPPARβ/δ and abolished the effect of LPS under hyperglycemia, which indicates on the agonist possible role as an anti-inflammatory agent under high glucose concentrations. Expand
PPARγ
Interest in peroxisome proliferator-activated receptors (PPARs) has steadily increased over the past 15 years. The recognition that subclasses of this receptor played critical roles in regulation ofExpand
...
1
2
3
4
...

References

SHOWING 1-10 OF 25 REFERENCES
Peroxisome Proliferator-Activated Receptor α (PPARα) down-regulation in cystic fibrosis lymphocytes
TLDR
Lymphocytes are important regulators of the inflammatory response by releasing cytokines and antibodies, and the diminished lymphocytic expression and activity of PPARα may contribute to the inflammatory processes that are observed in CF. Expand
PPARα downregulates airway inflammation induced by lipopolysaccharide in the mouse
TLDR
The data clearly show that PPARα downregulates cell infiltration, chemoattractant production and enhanced MMP activity triggered by LPS in mouse lung, suggesting thatPPARα activation may have a beneficial effect in acute or chronic inflammatory airway disorders involving neutrophils and macrophages. Expand
Peroxisome proliferator activated receptor-alpha expression in human liver.
TLDR
The results suggest that although humans retain the coding potential for a functional receptor, the low levels of PPAR alpha expression in liver may be insufficient to compete effectively with other proteins that bind to peroxisome proliferator response elements. Expand
Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators
TLDR
It is concluded that activators of PPARα inhibit the inflammatory response of aortic smooth-muscle cells and decrease the concentration of plasma acute-phase proteins, indicating that PPAR α in the vascular wall may influence the process of atherosclerosis and re-stenosis. Expand
Inhibition of NF-kappaB signaling by fenofibrate, a peroxisome proliferator-activated receptor-alpha ligand, presents a therapeutic strategy for rheumatoid arthritis.
TLDR
Results indicate that fenofibrate suppresses the development of arthritis by inhibition of NF-kappaB signaling; therefore, this compound offers possible anti-rheumatic drug. Expand
Regulation of the peroxisome proliferator-activated receptor alpha gene by glucocorticoids.
TLDR
The PPAR alpha gene is an early response gene of glucocorticoids that control its expression at the transcriptional level, and it is demonstrated that the expression of the peroxisome proliferator-activated receptor alpha (PPAR alpha) is regulated by glucOCorticoid hormones in hepatocytes. Expand
Expression of the Peroxisome Proliferator-activated Receptor Gene Is Stimulated by Stress and Follows a Diurnal Rhythm (*)
TLDR
Results show that regulation of the PPARα expression levels efficiently modulates PPAR activator signaling and thus may affect downstream metabolic pathways involved in lipid homeostasis. Expand
TNF‐α downregulates the peroxisome proliferator activated receptor‐α and the mRNAs encoding peroxisomal proteins in rat liver
TLDR
The mRNA for β‐actin was markedly increased implying that the effect of TNF on PPAR‐α and the peroxisomal mRNAs is highly selective, which may have important implications in perturbation of the lipid metabolism induced by TNF‐α. Expand
Peroxisome proliferator-activated receptor expression is reduced in skeletal muscle in COPD
TLDR
PPAR-δ and TFAM protein content, as well as PGC-1α mRNA levels, were decreased in the skeletal muscle of COPD patients compared with healthy controls and the cachectic COPD subgroup was further characterised by decreased PPAR-α mRNA expression and decreased TFAMprotein and mRNA levels compared with noncachectic COPd patients. Expand
Regulation of inflammation by PPARs: a future approach to treat lung inflammatory diseases?
TLDR
The present article reviews the current knowledge of the role of PPARα and PPARγ in controlling inflammation, and presents different findings suggesting that PPAR α andPPARγ activators may be helpful in the treatment of lung inflammatory diseases. Expand
...
1
2
3
...